Pages that link to "Q28249721"
Jump to navigation
Jump to search
The following pages link to Future drugs for migraine (Q28249721):
Displaying 13 items.
- Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis (Q34094599) (← links)
- CGRP receptor antagonists: an expanding drug class for acute migraine? (Q34637610) (← links)
- Increased asymmetric dimethylarginine and nitric oxide levels in patients with migraine (Q34770955) (← links)
- Chronic daily headaches (Q36239475) (← links)
- Increased serum levels of brain-derived neurotropic factor during migraine attacks: a pilot study (Q36261123) (← links)
- Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine (Q36261201) (← links)
- Acupoint injection of onabotulinumtoxin A for migraines (Q36329577) (← links)
- Botulinum toxin type a therapy in migraine: preclinical and clinical trials (Q37631993) (← links)
- Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse? (Q37760087) (← links)
- Dispute settlement understanding on the use of BOTOX® in chronic migraine (Q42682895) (← links)
- Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats (Q46550880) (← links)
- The therapeutic potential of novel anti-migraine acute therapies (Q48715159) (← links)
- [Pain-relieving effect of CGRP antagonism on inflammatory pain] (Q85245886) (← links)